TY - JOUR
T1 - Accelerating stem cell trials for Alzheimer's disease
AU - Hunsberger, Joshua G.
AU - Rao, Mahendra
AU - Kurtzberg, Joanne
AU - Bulte, Jeff W.M.
AU - Atala, Anthony
AU - LaFerla, Frank M.
AU - Greely, Henry T.
AU - Sawa, Akira
AU - Gandy, Sam
AU - Schneider, Lon S.
AU - Doraiswamy, P. Murali
PY - 2016/2/1
Y1 - 2016/2/1
N2 - At present, no effective cure or prophylaxis exists for Alzheimer's disease. Symptomatic treatments are modestly effective and offer only temporary benefit. Advances in induced pluripotent stem cell (iPSC) technology have the potential to enable development of so-called disease-in-a-dish personalised models to study disease mechanisms and reveal new therapeutic approaches, and large panels of iPSCs enable rapid screening of potential drug candidates. Different cell types can also be produced for therapeutic use. In 2015, the US Food and Drug Administration granted investigational new drug approval for the first phase 2A clinical trial of ischaemia-tolerant mesenchymal stem cells to treat Alzheimer's disease in the USA. Similar trials are either underway or being planned in Europe and Asia. Although safety and ethical concerns remain, we call for the acceleration of human stem cell-based translational research into the causes and potential treatments of Alzheimer's disease.
AB - At present, no effective cure or prophylaxis exists for Alzheimer's disease. Symptomatic treatments are modestly effective and offer only temporary benefit. Advances in induced pluripotent stem cell (iPSC) technology have the potential to enable development of so-called disease-in-a-dish personalised models to study disease mechanisms and reveal new therapeutic approaches, and large panels of iPSCs enable rapid screening of potential drug candidates. Different cell types can also be produced for therapeutic use. In 2015, the US Food and Drug Administration granted investigational new drug approval for the first phase 2A clinical trial of ischaemia-tolerant mesenchymal stem cells to treat Alzheimer's disease in the USA. Similar trials are either underway or being planned in Europe and Asia. Although safety and ethical concerns remain, we call for the acceleration of human stem cell-based translational research into the causes and potential treatments of Alzheimer's disease.
UR - http://www.scopus.com/inward/record.url?scp=84955407708&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84955407708&partnerID=8YFLogxK
U2 - 10.1016/S1474-4422(15)00332-4
DO - 10.1016/S1474-4422(15)00332-4
M3 - Review article
AN - SCOPUS:84955407708
VL - 15
SP - 219
EP - 230
JO - The Lancet Neurology
JF - The Lancet Neurology
SN - 1474-4422
IS - 2
ER -